chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received from a registered nurse concerning an approximate 22 year old female who in December 2007, was vaccinated with the first dose of GARDASIL. Concomitant therapy included YAZ. Subsequently the patient experienced numbness and tingling in both feet. The second dose of GARDASIL, 0.5 ml, IM was given between January 2006 and May 2008. The patient was seen by a neurologist who recommended that the patient not receive the third dose. The reporter felt that numbness and tingling in both feet was considered to be an other important medical event. Additional information has been requested.7/18/08-record received for DOS 6/27/08-neurology consultation for C/O numbness involving lower part of body present since January 2008 possibly due to Gardasil. PE: free of any objective abnormality.
Ultrasound done on 4-30-2021 for pain in calf of left leg and numbness of the toes for 7 days. Result came back positive for blood clot.
Shingles developed in left armpit, left arm, left side of chest, and left upper back.
This spontaneous report was received from a medical assistant, concerning 10 to 15 patients of an unknown age and gender. The patients' medical history, concurrent conditions, drug reactions or allergies were not reported. Concomitant medications included properly store sterile diluent (manufacturer unknown). On an unspecified day in August 2017, the patients were vaccinated with improperly stored doses of RECOMBIVAX HB from lot numbers N002920 and N002202; with expiration dates on 30-SEP-2018 and 04-NOV-2019, respectively. The storage temperature was 47 to 77 degrees Fahrenheit (°F) for a time frame of 30 minutes. There was also a previous temperature excursion of 47 to 77 degrees Fahrenheit (°F) for 15 minutes. No adverse effects were reported. No product quality complaint (PQC) was involved. This is one of several reports received from the same source. Sender's Comments: US-009507513-1708USA012976: US-009507513-1708USA012974: US-009507513-1708USA012975: US-009507513-1708USA011949: US-009507513-1708USA012973.
dry cough; fever; chills; This spontaneous case was reported by a consumer and describes the occurrence of COUGH (dry cough), PYREXIA (fever) and CHILLS (chills) in a 39-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 03-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-May-2021, the patient experienced PYREXIA (fever) and CHILLS (chills). On 05-May-2021, the patient experienced COUGH (dry cough). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. On 04-May-2021, PYREXIA (fever) and CHILLS (chills) had resolved. At the time of the report, COUGH (dry cough) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication was not provided Treatment medication include Tylenol .  The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) was not applicable.
About a week after 1st dose, I broke out in HIVES and was very itchy all over my arms, feet, and lower legs
Left arm swelling, redness, heated/ burning, bruise, rash, low grade fever 99.4, hardened area somewhat similar to a knot on site  Took Benedryl
It was reported at the time of the vaccination that the patient had no adverse effects, however on 10/01/2000 the patient broke out with a rash. On 10/03/2000 he was seen by a physician who reported that the rash looked like varicella. Follow up information from a physician reported that on 10/07/2000 the patient recovered. No further information is available.
This case was reported by a pharmacist via call center representative and described the occurrence of pneumonia in a male patient who received SHINGRIX. On an unknown date, the patient received SHINGRIX at an unknown dose. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced pneumonia (serious criteria GSK medically significant) and influenza-like symptoms. On an unknown date, the outcome of the pneumonia was not recovered/not resolved and the outcome of the influenza-like symptoms was recovered/resolved. It was unknown if the reporter considered the pneumonia to be related to SHINGRIX. The reporter considered the influenza-like symptoms to be probably related to SHINGRIX. Additional details were reported as follows: The age at vaccination was not reported. The patient experienced flu-like symptoms which resolved after 2 days. The patient was later diagnosed with pneumonia. The patient stated pneumonia had not resolved after a month. The healthcare professional did not collect patient or vaccine data. The information was given to the reporter in passing.
rash on her torso, back, and stomach; itchy; raised and blotchy; redder than her normal skin, as if she was flushed; This is a spontaneous report from a contactable consumer. An 88-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE) via an unspecified route of administration, administered in right arm on 18Feb2021 08:20 (Batch/Lot Number: EL9264), at the age of 88 years old, as dose 1, single for covid-19 immunisation. Medical history included allergy, high blood pressure, stomach discomfort, and allergic to penicillin, it happened recently, she was never allergic to penicillin for her whole life, and in the last couple months around summer she was. Concomitant medication included famotidine (PEPCID) taken for "stomach"; acetylsalicylic acid (BABY ASPIRIN); and a high blood pressure pill (unspecified). The reporter was stated that the patient received the 1st dose of the Pfizer-BioNTech Covid-19 Vaccine on 18Feb2021, and on 19Feb2021 reporter noticed that patient had a rash on her torso, back, and stomach. She does not have a rash at the injection site. She spoke to the doctor, the doctor said to call the experts at Pfizer. The reporter found out that patient should get the second shot in 21 days, but her second dose was scheduled in 18 days. She wanted to know if that is okay. The rash started the next day after the vaccination, it first started on the stomach and is now on her back, she also notices it is itchier. She has put her on diphenhydramine (BENADRYL). The rash had gotten lighter at the time of report. It was itchy. The reporter did not touch patient's rash and so the temper of her skin was unknown, she had been putting diphenhydramine cream on with Q-tips. She didn't have a fever. In texture the rash was raised and blotchy. In color, the rash was redder than her normal skin, as if she was flushed. The itchiness has improved, when it starts to itch again, she takes another diphenhydramine and it takes 4-6 hours then it wears off. The patient was recovering.  No follow-up attempts are possible. No further information is expected.
24 hours post vax the pt had a fever of 103, vomiting, the next day was ok. 5-7 days later got hives no other symptoms. Approximately 2-3 weeks later has round , red, slight raised rash, scattered on torso, backs of legs, which are occasionally itchy. The pt was seen by a physician.
pt reported 30-45 min post vacc. felt hot, red in face and hives.  Later developed Chest Pain
took 2nd vax & devel h/a, nausea; sinus started w/sneezing & runny nse; skin red 2SEp93 but rash appeared on front trunk of body & face 3SPE93; Took Hismanal due to allergies; rash & itching;
Information has been received from a healthcare worker (medical assistant) concerning a patient of unknown age and gender. The patient's medical history, concurrent condition and concomitant therapy were not provided. On 31-JUL-2012, the patient was vaccinated with the first dose of M-M-R II (lot #, expiration date, dose, and route unspecified). On 20-AUG-2012, the patient received the first dose of VARIVAX (Merck) (lot #, expiration date and route unspecified). Then, on 31-AUG-2012, the patient was administered the second dose of M-M-R II (lot #, expiration date, dose and route unspecified). No adverse effect was reported. Additional information has been requested.
Per employee report, "I received the covid booster in my right arm and it started to become painful approx. 2 hours after the injection. The spot was very high up and posterior to where it should have been given. I believe the vaccine was actually given in the joint and not the muscle. I had really limited ROM most of the weekend. I denied numbness and tingling.  I called employee health Friday 10/28 and they said to use tylenol and submit a HERO on Monday. I was to make an appointment with my PCP for follow-up next week if it doesn't improve. It is still bothersome but I am getting more ROM every day. I will schedule an appointment by Weds if it doesn't continue to improve." RN did call employee on Tuesday 11/1/22 to check in. Employee reports right arm is still painful, but ROM has improved. Will continue to monitor and follow-up with PCP as needed.
Patient called on 8/4/23 stated that her  injection site were swallen , red , painful and Nausea occurred.
I had a bad reaction after the second dose but nothing surprising.  Around September 21 I noticed a lump in my breast. I called to see if I can get in right away. I was told it was a new doctor and I couldn't. I had an appt the following Tuesday on Sept 28th. Dr.  agreed it was problematic and got me an appointment with Dr. on Sept 29th. I had a mammogram, sonogram, and biposy. On Friday Oct 1 I received news that I have an invasive carcinoma in my left breast and lymph nodes (grade 3). I later learned that it was a triple negative cancer.  I have no history of breast cancer in my family, eat healthy, exercise an hour a day, and believe this was from the virus after finding over 20 reports online.
anaphylaxis reaction; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP), Program ID: (RA). The reporter is the patient.  An elderly female patient received BNT162b2 (BNT162B2 NOS), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: ANAPHYLACTIC REACTION (medically significant), outcome "unknown", described as "anaphylaxis reaction".  Clinical course: It was reported that the outcome of the event as unknown and considered that the event was caused by the suspect product. The patients age was reported in the group of 50-99 years.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
5 minutes after receiving the vaccine I was driving home when my vision and hearing started swimming and I felt very nauseous and like I was about to lose consciousness. I narrowly avoided an accident and was able to pull over. Thankfully my vision and hearing returned to normal after about another five to ten minutes. I have never had a reaction to a vaccine like this before - it was a terrifying experience.
Reddened area to right arm, moderate swelling, warmth. Given Benadryl.
high fever, body aches, nausea; hand numb, itching started Sunday, clearing throat Saturday; headache, Yesterday - lymph nodes shoulder, neck, arms red, ears red; lips numb
initially started as a burning sensation on the left side of his body; rashes starting to come out; shingles really bad; This spontaneous case was reported by a consumer and describes the occurrence of HERPES ZOSTER (shingles really bad), BURNING SENSATION (initially started as a burning sensation on the left side of his body) and RASH (rashes starting to come out) in a 45-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029H21B) for COVID-19 vaccination.     No Medical History information was reported.    On 06-Jan-2022, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 16-Jan-2022, the patient experienced HERPES ZOSTER (shingles really bad) and RASH (rashes starting to come out). On an unknown date, the patient experienced BURNING SENSATION (initially started as a burning sensation on the left side of his body). At the time of the report, HERPES ZOSTER (shingles really bad), BURNING SENSATION (initially started as a burning sensation on the left side of his body) and RASH (rashes starting to come out) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter. Patient was prescribed with an antiviral. Reportedly, Patient went to an immediate care clinic. Additionally, It was reported that patients second dose of vaccine was schedule on 03-Feb-2022.
Information has been received from a consumer concerning her son with milk allergy, banana allergy, wheat and dairy, who on 19-JAN-2007 was vaccinated with a dose of ATTENUVAX.  There was no concomitant medication.  In approximately June 2007 (reported as after vaccination), the patient experienced fever which lasted for 3 days.  On an unspecified date the patient was seen by his physician.  Subsequently, the patient recovered from fever.  The patient subsequently experienced fever while on therapy with MERUVAX.  This is one report from several from the same source.  Additional information has been requested.
Received 1st dose of covid vaccine is due for 2nd dose next week. Pretty sure in between she had covid virus.; This is a spontaneous report from a Pfizer-sponsored program. A contactable female consumer reported for herself that she received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot number: unknown), via an unspecified route of administration on an unspecified date at single dose for COVID-19 immunisation. The patient had received first dose of COVID vaccine and was due for second dose next week. The patient was pretty sure that she had COVID virus in between. The patient had clarified that she was not underwent testing. The patient wanted to know if she should get second dose of COVID vaccine. The outcome of the event was unknown. No follow-up attempts are possible; information about lot/batch number cannot been obtained
A few days after the vaccine I developed severe fatigue and became really tired causing me to fall asleep really early,  I just couldn't keep my eyes open and for the next few days I had a hard time just getting out of bed and was very draggy. Brain fog and slow processing of information was associated. I just felt really drained and tired for about 2.5 days and began to feel a little better within a few days later.
DTaP inadvertently given instead of Tdap. No adverse reactions reported at this time.
RIGHT SIDED HEADACHE AND LEFT TEMPLE PAIN; This spontaneous report received from a consumer concerned a 22 year old male. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805018, and expiry: UNKNOWN) dose was not reported, administered on 09-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On 09-MAR-2021, the subject experienced right sided headache and left temple pain. Laboratory data included: Pain scale (NR: not provided) 5 to 6. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from right sided headache and left temple pain. This report was non-serious.; Sender's Comments: V0: Medical assessment comment not required as per standard procedure as case assessed as non-serious.
MA Administered vaccines below from the adult state stock to a 16 year old patient with no insurance. Provider will contact patient.  -  Hep A Havrix adult, Hep B Heplisav Adult, HPV Gardasil 9, and TDAP Boostrix
After receiving the Tdap - BOOSTRIX PFS from GlaxoSmithKline, I began having severe aching and stiffness in my neck and shoulders. The following day, I had noticeably enlarged lymph nodes along my collarbone, which were painful to touch. These symptoms lasted for close to 2 weeks. Since that time, I have had joint pain in my hips, knees, ankles and elbows off and on. I did not have these pains before, but did not think they could be related to the vaccine. Now, I'm not so sure.
Client presented to ED 10/29/06 with lower extremity weakness and pain. He was admitted to the Med/surg unit for testing. CT unremarkable, EMG studies showed demyelinating polyneuropathy. CSF protein slightly elevated. A few days later was admitted to Critical Care Unit due to increased weakness and paralysis. Shortly after admission to CCU, was intubated and dialyzed. He is now undergoing plasmaphoresis treatment. He has been positively diagnosed with Guillan-Barre Syndrome.
The pt experienced varicella disease 5 days post varicella vax. The pt had been exposed to the disease).
Myocarditis; This literature-non-study case was reported in a literature article and describes the occurrence of MYOCARDITIS (Myocarditis) in a 23-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.       No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced MYOCARDITIS (Myocarditis) (seriousness criterion medically significant). At the time of the report, MYOCARDITIS (Myocarditis) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered MYOCARDITIS (Myocarditis) to be related.    Concomitant and treatment medication was not reported.  It was reported that the authors presented a patient who is typical of a patient presenting with myocarditis post-COVID-19 mRNA- 1273 Moderna vaccination (young males, onset several days after second dose of the mRNA vaccine, and excellent short term complete recovery). Follow-up at 128 days revealed no residual sequelae in the patient.  Company comment: This case concerns a 23-year-old male patient with no medical history provided who experienced serious expected event of special interest Myocarditis. As per RA, the event occurred several days after the second dose of mRNA-1273. At the time of the report, the event resolved. It was reported that follow-up at 128 days revealed no residual sequelae. No further information was provided. No information regarding laboratory nor diagnostic tests was provided. The Reporter assessed the event as related to the suspect product. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This case concerns a 23-year-old male patient with no medical history provided who experienced serious expected event of special interest Myocarditis. As per RA, the event occurred several days after the second dose of mRNA-1273. At the time of the report, the event resolved. It was reported that follow-up at 128 days revealed no residual sequelae. No further information was provided. No information regarding laboratory nor diagnostic tests was provided. The Reporter assessed the event as related to the suspect product. The benefit-risk relationship of mRNA-1273 is not affected by this report.
S: At 3:40pm, 47yo Male presented for worsening dizziness and vomitting x1 since first dose Moderna COVID vaccine this AM at 10:54am. Patient deteriorating and c/o additional chest pain during intake. Patient getting paler and significantly more dizzy. Per MD, 911 called for patient as he was developing visual disturbances.  B: Patient has severe anaphylaxis allergic reaction to penicillin and stated he took 3x Norco this Am. Prior to COVID vaccination, Advised patient that it is safer to consult with his PCP or our doctor here and then receive the COVID vaccine. Patient stated he would rather get the vaccine now and assume all responsibility.  Patient observed for 30 mins post-vaccination. At approx. 1110, patient felt dizzy.  After crackers and Apple juice, patient stated he felt better. Prior to discharge at 1125, verified with patient that he no longer feels any symptoms.  A: At 3:40p, Vitals taken, WNL. Patient immediately assessed by urgent care MD, hemoglobin & Blood glucose WNL. EKG performed per MD. Ambulance called per MD at 3:53pm. 4:00pm EMS arrived. 4:09pm Patient left for Hospital.
patient was a resident of Health and Rehabilitation Center. Was symptomatic on 12/15/2021. Death abstracted stated date of death 1/19/2022 at 01:00. client was fully vaccinated. no booster noted.
Initial onset of muscle aches especially in legs. A rash formed at the injection site - 2 inches wide & 3 inches long. The next day woke up feeling extremely lethargic - could not read or even watch TV- slept the whole day. Also broke out in itchy hives across my lower back. The following day still tired but not as bad. Continued to regain energy and improve for the rest of the week.
I have Bells Palsy  I know at least one other person who lives near me with the same  How can this be so rare ? I'm so afraid to get the second shot  Please tell me something
On 5/10/22 an MA was attaching a needle to a Vaxneuvance vaccine when the end of the syringe sheered off and was stuck in the hub of the needle.  Th item was Vaxeneuvance vaccine Lot number: U029559 NDC number: 0006-4329-01 EXP: 11/16/22 . Item was disposed of, see attached pictures.
ACUTE DVT OF RIGHT LEG, UNSPECIFIED VEIN ACUTE DVT OF LEFT LEG, UNSPECIFIED VEIN ACUTE DVT, UNSPECIFIED VEIN 1/8/2023  &  1/25/2023  --  RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
About 30 minutes after injection had swelling and tingling  of lips. Had itching and tingling of hands about an hour later. Eyes with itching and mild wheezing began 2 hours after injection. Symptoms came and went for next 6 hours. Day after injection had light rash and itching over arms and legs that lasted for 24 hours.  On second day after injection only itching of skin.  Did not take any medications to stop symptoms. I am a physician and felt comfortable self monitoring.
It has been more than 2 months after receiving the first dose and she has not received the second; This spontaneous case was reported by a patient and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (It has been more than 2 months after receiving the first dose and she has not received the second) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (It has been more than 2 months after receiving the first dose and she has not received the second). At the time of the report, PRODUCT DOSE OMISSION ISSUE (It has been more than 2 months after receiving the first dose and she has not received the second) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medications were not provided by the reporter.  Treatment medications were not provided by reporter.; Sender's Comments: This report refers to a case of  Product dose omission issue for mRNA-1273,  with no associated AEs.
05dec89 pt vax hepta B. pt reported jaundiced but at no time were her eyes yellow nor was urine dark.  Pt developed enlarged lymph nodes.
Patient developed Rash & Redness on the face, trunk, extremities 1-2 minutes after Rotateq given by mouth. Given 1 dose of Benadryl. Recheck in 30 minutes, Rash & Redness improved. VS stable - No other side effects.
Vaccine administered on 3/1/01. Broke out with a rash on legs and increased on 3/8/01. Increased rash to torso; rash is itching. Advised to bathe with Aveeno or oatmeal.